[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","icd0gmcn53kn2vgyoh2zg8eiv","revision",2,"title","Clearmind Medicine Inc. 6-K 报告","originalTitle","6-K - Clearmind Medicine Inc. (0001892500) (Filer)","summary","Clearmind Medicine Inc. 于 2026 年 10 月 8 日提交 6-K 报告，附上题为“Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder”的新闻稿。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-08T11:55:40.000Z","discoveredAt","2026-10-08T12:11:31.578Z","timelineAt","category","tip","tags",[81,82],"stockSymbols",[80],"score",17,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fptimnnOOt34",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","161a16d4-ae5c-4841-98a1-dc9306fd38ef","Clearmind医药向FDA提交迷幻疗法建议",{"_72":73,"_15":74},"zh","

UNITED\nSTATES

SECURITIES\nAND EXCHANGE COMMISSION

Washington,\nD.C. 20549

Form\n6-K

Report\nof Foreign Private Issuer

Pursuant\nto Rule 13a-16 or 15d-16

under\nthe Securities Exchange Act of 1934

For\nthe month of: October 2026

Commission\nfile number: 001-41557

CLEARMIND\nMEDICINE INC.

(Translation\nof registrant’s name into English)

101\n– 1220 West 6th Avenue

Vancouver,\nBritish Columbia

(Address\nof principal executive offices)

Indicate\nby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form\n20-F ☒ Form 40-F ☐

CONTENTS

Attached\nhereto and incorporated herein is the Registrant’s press release issued on October 8, 2026, titled “Clearmind Announces Patent\nPublication in Japan Covering Treatment for Neurological Movement Disorder.”

EXHIBIT\nINDEX

\n \n \n \n \n \n \n \n \n

Exhibit No.
99.1		Press release titled: “Clearmind Announces\n Patent Publication in Japan Covering Treatment for Neurological Movement Disorder”

SIGNATURES

Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned, thereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	Clearmind Medicine, Inc.
	(Registrant)

Date: October 8, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

","zhKind","complete","CMND","政策与监管","IPO","aihot","/items/icd0gmcn53kn2vgyoh2zg8eiv","https://www.sec.gov/Archives/edgar/data/1892500/000121390026107727/0001213900-26-107727-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791676800&sig=72c3b858af523efd","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791676800&sig=7a11775d33e5ce74 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791676800&sig=6814978d6a0138cf 96w","changelogVersion","2026-10-01T08:00"]